Amit Sanyal, MD: A Clinician’s Perspective

First International Summit on Interventional Pharmacoeconomics

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Clifford A. Hudis, MD, and Allen S. Lichter, MD, on Oncology Drug Pricing in the United States: What You Need to Know

Allen S. Lichter, MD, of the Value in Cancer Care Consortium, interviews Clifford A. Hudis, MD, Chief Executive Officer of ASCO, on the question of whether cancer drug prices in the United States are the problem, or just the symptom, of a larger systemic issue.

Peter Clark, MA, MD, FRCP: A Payer Perspective

Jun

Today In Oncology

Amit Sanyal, MD: A Clinician’s Perspective

Related Videos

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Clifford A. Hudis, MD, and Allen S. Lichter, MD, on Oncology Drug Pricing in the United States: What You Need to Know

Peter Clark, MA, MD, FRCP: A Payer Perspective

Rates of Breast, CRC Screenings Almost Four Times Higher Than Lung Cancer Screenings

Frailty Following Chemotherapy May Be Linked to Poorer Survival in Older Women With Breast Cancer

Poor Agreement Reported Among Diagnostic Tests for Breast Cancer Related Lymphedema

Metabolic Syndrome May Increase Risk of Cancer Recurrence Subsequent Mortality Among Breast Cancer Survivors

CAP Issues New and Updated Cancer Protocols